School head warns of 'righteous generation' of children

Although the company will continue to pursue «higher-risk, high reward» drug candidates such as pegilodecakin, these will be a smaller part of the portfolio in the future, said Chief Scientific Officer Daniel Skovronsky. Selpercatinib is the first drug from Loxo’s pipeline that Lilly has brought to market. Prior to the acquisition, Loxo won approval of […]

Полный текст